Home > Search Results

Results: 4

Screening for Cystic Fibrosis-Related Diabetes: A Systematic Review

Screening for Cystic Fibrosis-Related Diabetes: A Systematic Review

Health Technology Assessment - NIHR Journals Library

Version: May 2012

Treatment of hyperglycaemia in cystic fibrosis

The usual practice in health technology assessment of treatments is to rely on high-quality evidence from randomised controlled trials (RCTs). This is also the approach used by the Cochrane Collaboration, which is why the Cochrane review by Onady et al. (which is discussed below) concluded that no recommendation could be made from the current evidence base.

Executive summary

Cystic fibrosis (CF) is caused by a genetic defect. The defective gene has to be inherited from both parents. CF occurs in about 1 in every 2500 births in the UK. The effect is to make some normal bodily fluids much thicker and more viscous than usual, and this affects particularly the lungs and the digestive system. The lungs become prone to infection and subsequent damage, and the main cause of death in cystic fibrosis is respiratory failure.


‘In slightly less than 70 years, cystic fibrosis has moved from a little known genetic condition, usually fatal in infancy and early childhood, to a complex multisystem disorder which now affects as many adults as children’ (J Littlewood, Cystic Fibrosis Trust, 2007, personal communication; this quotation was formerly on the Cystic Fibrosis Trust website).

Recent Activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...